東方材料(603110.SH):董事及監事減持時間過半 尚未實施減持
格隆匯1月9日丨東方材料(603110.SH)公佈,公司董事王嶽法持有公司股份81萬股(均為IPO前取得的股份),佔公司股份總數的0.5635%。其中無限售條件流通股為81萬股,佔公司股份總數的0.5635%。
公司監事徐芳琴持有公司股份242.92萬股(均為IPO前取得的股份),佔公司股份總數的1.6900%。其中無限售條件流通股為242.92萬股,佔公司股份總數的1.6900%。
截止2020年1月9日,根據公司2019年9月11日發佈的減持預披露公告(2019-070)確定的減持時間已過半。在本次減持期間,王嶽法和徐芳琴未進行股份減持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.